PL2714707T3 - Krystalizacja chlorowodorku epirubicyny - Google Patents
Krystalizacja chlorowodorku epirubicynyInfo
- Publication number
- PL2714707T3 PL2714707T3 PL12735774T PL12735774T PL2714707T3 PL 2714707 T3 PL2714707 T3 PL 2714707T3 PL 12735774 T PL12735774 T PL 12735774T PL 12735774 T PL12735774 T PL 12735774T PL 2714707 T3 PL2714707 T3 PL 2714707T3
- Authority
- PL
- Poland
- Prior art keywords
- crystallization
- epirubicin hydrochloride
- epirubicin
- hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/56—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011103751A DE102011103751A1 (de) | 2011-05-31 | 2011-05-31 | Kristallisierung von Epirubicinhydrochlorid |
US201161493034P | 2011-06-03 | 2011-06-03 | |
EP12735774.7A EP2714707B1 (de) | 2011-05-31 | 2012-05-25 | Kristallisierung von epirubicinhydrochlorid |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2714707T3 true PL2714707T3 (pl) | 2017-06-30 |
Family
ID=47173398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12735774T PL2714707T3 (pl) | 2011-05-31 | 2012-05-25 | Krystalizacja chlorowodorku epirubicyny |
Country Status (14)
Country | Link |
---|---|
US (1) | US9657047B2 (pl) |
EP (1) | EP2714707B1 (pl) |
JP (2) | JP6014844B2 (pl) |
KR (1) | KR20140006092A (pl) |
CN (1) | CN103827129A (pl) |
AR (1) | AR086519A1 (pl) |
AU (1) | AU2012265238B2 (pl) |
DE (1) | DE102011103751A1 (pl) |
HR (1) | HRP20170329T1 (pl) |
HU (1) | HUE031795T2 (pl) |
PL (1) | PL2714707T3 (pl) |
RU (1) | RU2586117C2 (pl) |
TW (1) | TWI496789B (pl) |
WO (1) | WO2012163508A1 (pl) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2778171A1 (en) * | 2013-03-15 | 2014-09-17 | Synbias Pharma Ltd. | Crystalline monohydrate of epirubicin hydrochloride |
CN104861014B (zh) * | 2015-06-03 | 2017-09-29 | 道中道(菏泽)制药有限公司 | 一种盐酸表阿霉素结晶的制备方法 |
CN109384822B (zh) * | 2017-08-11 | 2021-08-03 | 鲁南制药集团股份有限公司 | 一种盐酸表柔比星晶型及其制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1506200A (en) | 1975-04-30 | 1978-04-05 | Farmaceutici Italia | Glycosides |
US4345068A (en) | 1979-11-22 | 1982-08-17 | Farmitalia Carlo Erba S.P.A. | Process for the preparation of 4'-epidaunorubicin, 3',4'-diepidaunorubicin, their doxorubicin analogs, and intermediates used in said process |
IT1155446B (it) | 1982-12-23 | 1987-01-28 | Erba Farmitalia | Procedimento per la purificazione di glucosidi antraciclinonici mediante adsobimento selettivo su resine |
GB8426672D0 (en) | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
ES2151632T3 (es) * | 1996-12-16 | 2001-01-01 | Pharmachemie Bv | Un proceso para preparar epirubicina o sales de adicion de acidos de la misma a partir de daunorubicina. |
DE69833220T2 (de) | 1997-11-28 | 2006-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | Kristallines amrubicin-hydrochlorid |
JP3900243B2 (ja) * | 1997-12-05 | 2007-04-04 | メルシャン株式会社 | 結晶質アントラサイクリン抗生物質およびその製造方法 |
KR20020071931A (ko) * | 2000-01-07 | 2002-09-13 | 트렌스폼 파마수티컬스 인코퍼레이티드 | 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석 |
WO2005004805A2 (en) * | 2003-07-02 | 2005-01-20 | Solux Corporation | Thermally stable crystalline epirubicin hydrochloride and method of making the same |
US20090099346A1 (en) * | 2003-07-02 | 2009-04-16 | Victor Matvienko | Thermally stable crystalline epirubicin hydrochloride |
US7388083B2 (en) * | 2005-03-07 | 2008-06-17 | Solux Corporation | Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics |
US20070004653A1 (en) * | 2005-05-11 | 2007-01-04 | Roberto Arosio | Stable lyophilized anthracycline glycosides |
US8802830B2 (en) * | 2005-12-20 | 2014-08-12 | Solux Corporation | Synthesis of epirubicin from 13-dihydrodaunorubicine |
JP2007261976A (ja) * | 2006-03-28 | 2007-10-11 | Meiji Seika Kaisha Ltd | 抗腫瘍性アンスラサイクリン系抗生物質の製造法 |
ES2644422T3 (es) | 2007-05-08 | 2017-11-28 | Provivo Oy | Cepas modificadas genéticamente que producen metabolitos de antraciclina útiles como fármacos para el cáncer |
ES2401555T3 (es) | 2008-06-18 | 2013-04-22 | Lexicon Pharmaceuticals, Inc. | Formas sólidas de (1R,2S,3R)-1-(2-(isoxazol-3-il)-1H-imidazol-4-il)butano-1,2,3,4-tetraol y métodos de utilización de las mismas |
PL2301943T3 (pl) * | 2009-09-08 | 2014-06-30 | Heraeus Precious Metals Gmbh | Krystalizacja epidaunorubicyny x HCI |
KR101125460B1 (ko) | 2010-03-24 | 2012-03-28 | 동아제약주식회사 | 에피루비신 염산염의 신규한 결정형 |
CN102120750B (zh) * | 2011-01-30 | 2013-04-03 | 山东新时代药业有限公司 | 一种盐酸表柔比星的纯化方法 |
-
2011
- 2011-05-31 DE DE102011103751A patent/DE102011103751A1/de not_active Ceased
-
2012
- 2012-05-15 US US13/471,537 patent/US9657047B2/en active Active
- 2012-05-22 AR ARP120101808A patent/AR086519A1/es not_active Application Discontinuation
- 2012-05-25 HU HUE12735774A patent/HUE031795T2/en unknown
- 2012-05-25 CN CN201280026091.5A patent/CN103827129A/zh active Pending
- 2012-05-25 JP JP2014513078A patent/JP6014844B2/ja active Active
- 2012-05-25 WO PCT/EP2012/002248 patent/WO2012163508A1/de active Application Filing
- 2012-05-25 PL PL12735774T patent/PL2714707T3/pl unknown
- 2012-05-25 AU AU2012265238A patent/AU2012265238B2/en active Active
- 2012-05-25 KR KR1020137031904A patent/KR20140006092A/ko active Search and Examination
- 2012-05-25 RU RU2013158684/04A patent/RU2586117C2/ru active
- 2012-05-25 EP EP12735774.7A patent/EP2714707B1/de active Active
- 2012-05-29 TW TW101119194A patent/TWI496789B/zh active
-
2016
- 2016-05-18 JP JP2016099985A patent/JP2016175938A/ja active Pending
-
2017
- 2017-02-27 HR HRP20170329TT patent/HRP20170329T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
CN103827129A (zh) | 2014-05-28 |
HUE031795T2 (en) | 2017-08-28 |
DE102011103751A1 (de) | 2012-12-06 |
EP2714707B1 (de) | 2016-12-14 |
AU2012265238A1 (en) | 2014-01-09 |
TWI496789B (zh) | 2015-08-21 |
WO2012163508A1 (de) | 2012-12-06 |
US20120309948A1 (en) | 2012-12-06 |
AU2012265238B2 (en) | 2016-05-12 |
US9657047B2 (en) | 2017-05-23 |
AR086519A1 (es) | 2013-12-18 |
TW201302773A (zh) | 2013-01-16 |
EP2714707A1 (de) | 2014-04-09 |
HRP20170329T1 (hr) | 2017-04-21 |
KR20140006092A (ko) | 2014-01-15 |
JP2014515381A (ja) | 2014-06-30 |
JP2016175938A (ja) | 2016-10-06 |
RU2013158684A (ru) | 2015-07-10 |
JP6014844B2 (ja) | 2016-10-26 |
RU2586117C2 (ru) | 2016-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244183A1 (zh) | Ivacaftor的氘化衍生物 | |
HK1199728A1 (en) | Polymorphic form of pridopidine hydrochloride | |
EP2596675A4 (en) | METHODS OF MANAGING MULTIPLE TIME ADVANCE GROUPS | |
HUE047354T2 (hu) | Ivacaftor deuterizált származékai | |
EP2742051A4 (en) | AMORPHIC FORM OF DOLUTEGRAVIR | |
IL230976A0 (en) | Crystalline forms of cvezitaxel | |
HK1192562A1 (zh) | 取代的苯甲酰胺衍生物 | |
PL2505243T3 (pl) | Urządzenie do krystalizacji | |
IL233001A0 (en) | New iso-ergoline histories | |
GB2512737B (en) | Micro-Fermentation of cocoa | |
EP2737805A4 (en) | IMPROVED CHOCOLATE FRIENDLY | |
EP2684869A4 (en) | PREPARATION OF 3-MERCAPOTOPROPIONATES | |
EP2680843A4 (en) | DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS | |
PL2714707T3 (pl) | Krystalizacja chlorowodorku epirubicyny | |
SG10201607229XA (en) | Crystallization methods | |
IL230977A (en) | A crystalline form of relapaldib | |
EP2782902A4 (en) | DERIVATIVES FROM PHENOXYISOBUTTERIC ACID | |
PL395425A1 (pl) | Sposób wytwarzania chlorowodorku 2-amino-N-tert-butylo-2- cyjanoacetamidu | |
GB201102475D0 (en) | Method of reducing offset | |
IL231452A (en) | An amorphous form of a dolotgrave | |
PL120112U1 (pl) | Pustak scienny | |
PL119877U1 (pl) | Pustak scienny | |
GB201100642D0 (en) | Clock adjustment |